Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor


Creative Commons License

Cetin B., Kaplan M. A. , Berk V., Tufan G., Benekli M., Isikdogan A., ...More

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.43, no.1, pp.28-32, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 1
  • Publication Date: 2013
  • Doi Number: 10.1093/jjco/hys175
  • Journal Name: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.28-32
  • Gazi University Affiliated: Yes

Abstract

Surgical resection of asymptomatic primary colorectal cancer in patients presenting with synchronous unresectable metastatic disease is controversial. Concerns and controversies remain over combining cytotoxic chemotherapy with bevacizumab in this patient population.